Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05450562 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT05450562 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 33 participants.
The verdict
NCT05450562, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents for participants aged at least 18 years with previously treated metastatic malignancies.
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL SAR444200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-09-20 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05450562
The ClinicalTrials.gov registry entry for NCT05450562 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05450562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05450562 about?
NCT05450562 is a clinical study titled "Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors". This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents for participants aged at least 18 years with previously treated metastatic malignancies.
What is the current status of trial NCT05450562?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-09-20. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT05450562?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), SAR444200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05450562?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.